Beryl Drugs Ltd
Incorporated in 1993, Beryl Drugs Ltd
is in the business of pharmaceuticals manufacturing[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Number of Channel Partners count ・Standalone data |
|
||||||
| Number of Corporate Customers count ・Standalone data |
|||||||
| Number of Marketing Offices in India count ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliance-57 (5) : intimation after the end of quarter
- Filed Regulation 74(5) certificate and Regulation 57(5) non-applicability for quarter ended 30 September 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DP) REGULATIONS, 2018 FOR THE QUARTER ENDED 30.09.2026
-
Closure of Trading Window
- Trading window closed from 1 October 2026 until 48 hours after Q2 FY2026 results.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING HELD ON 29TH SEPTEMBER, 2026
- 33rd AGM held on 29 Sept 2026; shareholders approved financials, director reappointment, and related-party transaction limit.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
BDL is mainly engaged in the domestic, institutions, and export supply of bulk drugs, pharmaceuticals, and healthcare products
like I.V. Fluids and Small Volume Injectables.
It manufactures and markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network and provides research and development, contract manufacturing services, and veterinary products.